Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients with advanced renal cell carcinoma (kidney cancer). Most patients, however, eventually experience disease progression, ...
Apr 3, 2023
0
4
For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing—called cryoablation—yields a lower-risk of cancer-related death compared ...
Nov 29, 2022
0
2
The most comprehensive study of kidney cancer at single-cell level has discovered a potential drug target to treat renal cell carcinoma, a cancer with a high mortality rate that is hard to detect. Researchers from the Wellcome ...
Nov 25, 2022
0
853
Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient's chances of survival. This is shown by researchers from ...
Oct 17, 2022
0
66
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
16
Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established ...
Aug 17, 2022
0
15
An international group of researchers investigated why mutations often associated with renal cancer result specifically in renal cancer, instead of other cancer types.
Aug 9, 2022
0
85
The formation of new blood vessels, also known as angiogenesis, is critical to the development and progression of cancer. Angiogenesis is controlled by many different protein messengers that can either stimulate or inhibit ...
Jul 8, 2022
0
13
Kidney cancer accounts for only 4% of all cancers in the United States; however, its incidence has more than doubled since 1975, with the most common type being clear cell renal cell carcinoma. While outcomes of patients ...
Jul 8, 2022
0
60
Investigators from UCLA Jonsson Comprehensive Cancer Center have identified a germline biomarker signature that successfully predicts which patients will suffer serious side effects that occur in up to 3 in ten patients on ...
Feb 3, 2022
0
29
